Skip to main content

Dimetapp Children's Cold & Allergy Disease Interactions

There are 8 disease interactions with Dimetapp Children's Cold & Allergy (brompheniramine / phenylephrine).

Major

Sympathomimetics (applies to Dimetapp Children's Cold & Allergy) cardiovascular disease

Major Potential Hazard, High plausibility. Applicable conditions: Cerebrovascular Insufficiency, Hyperthyroidism, Pheochromocytoma

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

References

  1. Humberstone PM (1969) "Hypertension from cold remedies." Br Med J, 1, p. 846
  2. Mariani PJ (1986) "Pseudoephedrine-induced hypertensive emergency: treatment with labetalol." Am J Emerg Med, 4, p. 141-2
  3. Rosen RA (1981) "Angina associated with pseudoephedrine ." Ann Emerg Med, 10, p. 230-1
  4. Wiener I, Tilkian AG, Palazzolo M (1990) "Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion." Cathet Cardiovasc Diagn, 20, p. 51-3
  5. Gordon RD, Ballantine DM, Bachmann AW (1992) "Effects of repeated doses of pseudoephedrine on blood pressure and plasma catecholamines in normal subjects and in patients with phaeochromocytoma." Clin Exp Pharmacol Physiol, 19, p. 287-90
  6. Loizou LA, Hamilton JG, Tsementzis SA (1982) "Intracranial haemorrhage in association with pseudoephedrine overdose." J Neurol Neurosurg Psychiatry, 45, p. 471-2
  7. Dickerson J, Perrier D, Mayersohn M, Bressler R (1978) "Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man." Eur J Clin Pharmacol, 14, p. 253-9
  8. Wooten MR, Khangure MS, Murphy MJ (1983) "Intracerebral hemorrhage and vasculitis related to ephedrine abuse." Ann Neurol, 13, p. 337-40
  9. To LB, Sangster JF, Rampling D, Cammens I (1980) "Ephedrine-induced cardiomyopathy." Med J Aust, 2, p. 35-6
  10. Bruno A, Nolte KB, Chapin J (1993) "Stroke associated with ephedrine use." Neurology, 43, p. 1313-6
  11. Stoessl AJ, Young GB, Feasby TE (1985) "Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics." Stroke, 16, p. 734-6
  12. Covington TR, eds., Lawson LC, Young LL (1993) "Handbook of Nonprescription Drugs." Washington, DC: American Pharmaceutical Association
  13. (2001) "Product Information. Sudafed (pseudoephedrine)." Glaxo Wellcome
  14. Kizer KW (1984) "Intracranial hemorrhage associated with overdose of decongestant containing phenylpropanolamine" Am J Emerg Med, 2, p. 180-1
  15. Edwards M, Russo L, Harwood-Nuss A (1987) "Cerebral infarction with a single oral dose of phenylpropanolamine." Am J Emerg Med, 5, p. 163-4
  16. Lake CR, Gallant S, Masson E, Miller P (1990) "Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports." Am J Med, 89, p. 195-208
  17. Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B (1989) "Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study." Am J Med, 86, p. 427-32
  18. Lake CR, Zaloga G, Clymer R, Quirk RM, Chernow B (1988) "A double dose of phenylpropanolamine causes transient hypertension." Am J Med, 85, p. 339-43
  19. Bernstein E, Diskant BM (1982) "Phenylpropanolamine: a potentially hazardous drug." Ann Emerg Med, 11, p. 311-5
  20. Kroenke K, Omori DM, Simmons JO, Wood DR, Meier NJ (1989) "The safety of phenylpropanolamine in patients with stable hypertension." Ann Intern Med, 111, p. 1043-4
  21. Pentel PR, Mikell FL, Zavoral JH (1982) "Myocardial injury after phenylpropanolamine ingestion." Br Heart J, 47, p. 51-4
  22. Howrie DL, Wolfson JH (1983) "Phenylpropanolamine-induced hypertensive seizures." J Pediatr, 102, p. 143-5
  23. Horowitz JD, Lang WJ, Howes LG, Fennessy MR, Christophidis N, Rand MJ, Louis WJ (1980) "Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations." Lancet, 1, p. 60-1
  24. Johnson DA, Etter HS, Reeves DM (1983) "Stroke and phenylpropanolamine use" Lancet, 2, p. 970
  25. McEwen J (1983) "Phenylpropanolamine-associated hypertension after the use of "over- the-counter" appetite-suppressant products." Med J Aust, 2, p. 71-3
  26. Elliott CF, Whyte JC (1981) "Phenylpropanolamine and hypertension." Med J Aust, 1, p. 715
  27. Maher LM, Peterson PL, Dela-Cruz C (1987) "Postpartum intracranial hemorrhage and phenylpropanolamine use" Neurology, 37, p. 1686
  28. Kase CS, Foster TE, Reed JE, Spatz EL, Girgis GN (1987) "Intracerebral hemorrhage and phenylpropanolamine use." Neurology, 37, p. 399-404
  29. Kikta DG, Devereaux MW, Chandar K (1985) "Intracranial hemorrhages due to phenylpropanolamine." Stroke, 16, p. 510-2
  30. Clark JE, Simon WA (1983) "Cardiac arrhythmias after phenylpropanolamine ingestion." Drug Intell Clin Pharm, 17, p. 737-8
  31. Noble R (1988) "A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine." Drug Intell Clin Pharm, 22, p. 296-9
  32. O'Connell MB, Gross CR (1991) "The effect of multiple doses of phenylpropanolamine on the blood pressure of patients whose hypertension was controlled with beta blockers." Pharmacotherapy, 11, p. 376-81
  33. O'Connell MB, Gross CR (1990) "The effect of single-dose phenylpropanolamine on blood pressure in patients with hypertension controlled by beta blockers." Pharmacotherapy, 10, p. 85-91
  34. Chin C, Choy M (1993) "Cardiomyopathy induced by phenylpropanolamine." J Pediatr, 123, p. 825-7
  35. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
  36. Lee KY, Beilin LJ, Vandongen R (1979) "Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin." Lancet, 1, p. 1110-1
  37. Gibson GJ, Warrell DA (1972) "Hypertensive crises and phenylpropanolamine." Lancet, 2, p. 492-3
  38. Frewin DB (1983) "Phenylpropanolamine. How safe is it?" Med J Aust, 2, p. 54-5
  39. Lee KY, Beilin LJ, Vandongen R (1979) "Severe hypertension after administration of phenylpropanolamine" Med J Aust, 1, p. 525-6
  40. Horowitz JD, McNeil JJ, Sweet B, Mendelsohn FA, Louis WJ (1979) "Hypertension and postural hypotension induced by phenylpropanolamine (Trimolets)." Med J Aust, 1, p. 175-6
  41. Frewin DB, Leonello PP, Frewin ME (1978) "Hypertension after ingestion of Trimolets." Med J Aust, 2, p. 497-8
  42. Teh AY (1979) "Phenylpropanolamine and hypertension" Med J Aust, 2, p. 425-6
  43. Shapiro SR (1969) "Hypertension due to anorectic agent." N Engl J Med, 280, p. 1363
  44. Maher LM, Peterson PL, Dela-Cruz C (1987) "Postpartum intracranial hemorrhage and phenylpropanolamine use." Neurology, 37, 1886,1890
  45. Fallis RJ, Fisher M (1985) "Cerebral vasculitis and hemorrhage associated with phenylpropanolamine." Neurology, 35, p. 405-7
  46. Caperton E (1983) "Raynaud's phenomenon. Role of diet pills and cold remedies." Postgrad Med, 73, p. 291-2
  47. McDowell JR, LeBlanc HJ (1985) "Phenylpropanolamine and cerebral hemorrhage." West J Med, 142, p. 688-91
  48. Williams DM (1990) "Phenylpropanolamine hydrochloride" Am Pharm, NS30, p. 47-50
  49. Dowse R, Scherzinger SS, Kanfer I (1990) "Serum concentrations of phenylpropanolamine and associated effects on blood pressure in normotensive subjects: a pilot-study." Int J Clin Pharmacol Ther Toxicol, 28, p. 205-10
  50. Pentel PR, Aaron C, Paya C (1985) "Therapeutic doses of phenylpropanolamine increase supine systolic blood pressure." Int J Obes, 9, p. 115-9
  51. Finton CK, Barton M, Chernow B (1982) "Possible adverse effects of phenylpropanolamine (diet pills) on sympathetic nervous system function--caveat emptor!" Mil Med, 147, p. 1072
  52. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
  53. Leo PJ, Hollander JE, Shih RD, Marcus SM (1996) "Phenylpropanolamine and associated myocardial injury." Ann Emerg Med, 28, p. 359-62
  54. Gill ND, Shield A, Blazevich AJ, Zhou S, Weatherby RP (2000) "Muscular and cardiorespiratory effects of pseudoephedrine in human athletes." Br J Clin Pharmacol, 50, p. 205-13
  55. Haller CA, Benowitz NL (2000) "Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids." N Engl J Med, 343, p. 1833-8
  56. Mansoor GA (2001) "Herbs and alternative therapies in the hypertension clinic." Am J Hypertens, 14(9 Pt 1), p. 971-5
  57. Samenuk D, Link MS, Homoud MK, et al. (2002) "Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine." Mayo Clin Proc, 77, p. 12-6
  58. (2016) "Product Information. Akovaz (ephedrine)." Eclat Pharmaceuticals
View all 58 references
Moderate

Antihistamines (applies to Dimetapp Children's Cold & Allergy) anticholinergic effects

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Urinary Retention, Glaucoma/Intraocular Hypertension

Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive. Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders. Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects. In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.

References

  1. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  2. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  3. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  4. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  5. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  6. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  7. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  8. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  9. (2001) "Product Information. Marezine (cyclizine)." Glaxo Wellcome
  10. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  11. (2001) "Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC
  12. (2001) "Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals
  13. (2001) "Product Information. Drixoral (dextromethorphan)." Schering-Plough
  14. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
  15. Watemberg NM, Roth KS, Alehan FK, Epstein CE (1999) "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics, 103, p. 158-60
  16. (2001) "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals
  17. (2001) "Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn
  18. (2001) "Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation
  19. (2001) "Product Information. Temaril (trimeprazine)." Allergan Inc
  20. Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG (1999) "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange
View all 20 references
Moderate

Antihistamines (applies to Dimetapp Children's Cold & Allergy) asthma/COPD

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Chronic Obstructive Pulmonary Disease

It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract. Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.

References

  1. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  2. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  3. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  4. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  5. (2001) "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories
  6. Maddox DE, Reed CE (1987) "Clinical pharmacodynamics of antihistamines." Ann Allergy, 59, p. 43-8
  7. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  8. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  9. (2001) "Product Information. Marezine (cyclizine)." Glaxo Wellcome
  10. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  11. (2001) "Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC
  12. (2001) "Product Information. Drixoral (dextromethorphan)." Schering-Plough
  13. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
  14. (2001) "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals
  15. (2001) "Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn
  16. (2001) "Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation
  17. (2001) "Product Information. Temaril (trimeprazine)." Allergan Inc
View all 17 references
Moderate

Antihistamines (applies to Dimetapp Children's Cold & Allergy) cardiovascular

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Hyperthyroidism, Hypotension

Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities. Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported. Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.

References

  1. Schuller DE, Turkewitz D (1986) "Adverse effects of antihistamines." Postgrad Med, 79, p. 75-86
  2. (2002) "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories
  3. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
  4. (2002) "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc
  5. (2002) "Product Information. Benadryl (diphenhydramine)." Parke-Davis
  6. (2001) "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation
  7. (2001) "Product Information. Antivert (meclizine)." Roerig Division
  8. (2001) "Product Information. Optimine (azatadine)." Schering Corporation
  9. Smith SJ (1994) "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg, 111 Suppl, p. 348-54
  10. (2001) "Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals
  11. Woosley RL (1996) "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol, 36, p. 233-52
  12. (2001) "Product Information. Drixoral (dextromethorphan)." Schering-Plough
  13. (2001) "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company
  14. (2001) "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals
  15. (2001) "Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn
View all 15 references
Moderate

Antihistamines (applies to Dimetapp Children's Cold & Allergy) renal/liver disease

Moderate Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction

Limited pharmacokinetic data are available for the older, first-generation antihistamines. Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation. Therapy with antihistamines should be administered cautiously in such patients. Lower initial dosages may be appropriate.

References

  1. Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI (1974) "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther, 16, p. 1066-76
  2. Paton DM, Webster DR (1985) "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet, 10, p. 477-97
  3. Rumore MM (1984) "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm, 18, p. 701-7
  4. Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL (1982) "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol, 22, p. 359-65
  5. Simons KJ, Simons FE, Luciuk GH, Frith EM (1984) "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci, 73, p. 595-9
  6. Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S (1984) "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther, 35, p. 474-9
  7. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI (1986) "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol, 26, p. 529-33
  8. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG (1975) "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm, 3, p. 159-70
  9. Simons FE, Frith EM, Simons KJ (1982) "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol, 70, p. 458-64
  10. Bruce RB, Turnbull LB, Newman JH, Pitts JE (1968) "Metabolism of brompheniramine." J Med Chem, 11, p. 1031-4
  11. Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ (1975) "Human metabolism of cyproheptadine." Drug Metab Dispos, 3, p. 189-97
  12. Hintze KL, Wold JS, Fischer LJ (1975) "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos, 3, p. 1-9
  13. Maddox DE, Reed CE (1987) "Clinical pharmacodynamics of antihistamines." Ann Allergy, 59, p. 43-8
  14. Simons FE, Simons KJ, Frith EM (1984) "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol, 73, p. 69-75
  15. Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ (1989) "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol, 29, p. 809-15
View all 15 references
Moderate

Sympathomimetics (applies to Dimetapp Children's Cold & Allergy) BPH

Moderate Potential Hazard, High plausibility. Applicable conditions: Benign Prostatic Hyperplasia, Prostate Tumor

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

References

  1. Covington TR, eds., Lawson LC, Young LL (1993) "Handbook of Nonprescription Drugs." Washington, DC: American Pharmaceutical Association
  2. (2001) "Product Information. Sudafed (pseudoephedrine)." Glaxo Wellcome
  3. Williams DM (1990) "Phenylpropanolamine hydrochloride" Am Pharm, NS30, p. 47-50
  4. (2016) "Product Information. Akovaz (ephedrine)." Eclat Pharmaceuticals
View all 4 references
Moderate

Sympathomimetics (applies to Dimetapp Children's Cold & Allergy) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

References

  1. Covington TR, eds., Lawson LC, Young LL (1993) "Handbook of Nonprescription Drugs." Washington, DC: American Pharmaceutical Association
  2. (2001) "Product Information. Sudafed (pseudoephedrine)." Glaxo Wellcome
  3. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
  4. Williams DM (1990) "Phenylpropanolamine hydrochloride" Am Pharm, NS30, p. 47-50
  5. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
  6. (2016) "Product Information. Akovaz (ephedrine)." Eclat Pharmaceuticals
View all 6 references
Moderate

Sympathomimetics (applies to Dimetapp Children's Cold & Allergy) glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.

References

  1. Covington TR, eds., Lawson LC, Young LL (1993) "Handbook of Nonprescription Drugs." Washington, DC: American Pharmaceutical Association
  2. (2001) "Product Information. Sudafed (pseudoephedrine)." Glaxo Wellcome
  3. Fraunfelder FT, Fraunfelder FW; Randall JA (2001) "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann

Dimetapp Children's Cold & Allergy drug interactions

There are 472 drug interactions with Dimetapp Children's Cold & Allergy (brompheniramine / phenylephrine).

Dimetapp Children's Cold & Allergy alcohol/food interactions

There is 1 alcohol/food interaction with Dimetapp Children's Cold & Allergy (brompheniramine / phenylephrine).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.